surfactant protein DGenealiases: COLEC7 · PSP-D · SFTP4 · SP-D
Q-omics provides the consensus-scored SFTPD profile across patient tissues and cancer cell-line models. SFTPD expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SFTPD is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, SFTPD RNA expression shows 18,665 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KICH, and LSCC as cancer lineages where SFTPD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTPD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTPD survival associations across molecular data types. SFTPD RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTPD RNA expression–survival associations across cancer types. High SFTPD expression shows unfavorable associations in LUSC, UCEC and ACC, but favorable associations in KIRP, BRCA and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SFTPD RNA expression.
This table summarizes SFTPD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SFTPD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTPD shows lower tumor expression in KICH, LUAD, COAD, LUSC, KIRP and THCA. The KICH box plot shows higher SFTPD RNA expression in normal versus tumor tissue (log2 FC = −2.610, t-test p < 0.001).
This table shows molecular features associated with SFTPD in patient tissues and cancer cell lines. In patient samples, SFTPD shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFTPD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and OVARY.
